[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06039033":3,"trial-entities:NCT06039033":84,"trial-summary:NCT06039033":87},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":15,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":26,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":15,"healthy_volunteers":36,"eligibility_criteria":37,"std_ages":47,"locations":50,"central_contacts":66,"overall_officials":69,"references":72,"see_also_links":83},"NCT06039033","90700326","Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns","Merkel Cell Carcinoma Clinical Trials: What Are Prevailing Patient Experiences in Merkel Cell Carcinoma Studies","NOT_YET_RECRUITING","2026-10","2023-09","2023-09-15","2024-10","Power Life Sciences Inc.","INDUSTRY",null,"Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.\n\nThis study will admit a wide range of data on the clinical trial experience of Merkel cell carcinoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Merkel cell carcinoma patients.",[18],"Merkel Cell Carcinoma",[18],"OBSERVATIONAL",[],{"count":23,"type":24},500,"ESTIMATED",[],[27,30],{"measure":28,"timeFrame":29},"Number of patients who decide to enroll in a Merkel cell carcinoma clinical research","3 months",{"measure":31,"timeFrame":32},"Rate of patients who remain in Merkel cell carcinoma clinical research to trial completion","12 months",[],"ALL","18 Years",false,{"inclusion":38,"exclusion":42,"raw_text":46},[39,40,41],"Aged ≥ 18 years old","Able to comprehend the investigational nature of the protocol and provide informed consent","Diagnosis of Merkel cell carcinoma",[43,44,45],"No diagnosis of Merkel cell carcinoma confirmed","Inability to perform regular electronic reporting","Patient does not understand, sign, and return consent form","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n* Diagnosis of Merkel cell carcinoma\n\nExclusion Criteria:\n\n* No diagnosis of Merkel cell carcinoma confirmed\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",[48,49],"ADULT","OLDER_ADULT",[51],{"facility":52,"city":53,"state":54,"zip":55,"country":56,"contacts":57,"geoPoint":63},"Power Life Sciences","San Francisco","California","94107","United States",[58],{"name":59,"role":60,"phone":61,"email":62},"Michael B Gill","CONTACT","415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"lat":64,"lon":65},37.77493,-122.41942,[67],{"name":59,"role":60,"phone":61,"email":68},"bask@withpower.com",[70],{"name":59,"affiliation":13,"role":71},"STUDY_DIRECTOR",[73,77,80],{"pmid":74,"type":75,"citation":76},"32472503","BACKGROUND","Lambert J, Marrel A, D'Angelo SP, Burgess MA, Chmielowski B, Fazio N, Gambichler T, Grob JJ, Lebbe C, Robert C, Russell J, Guzel G, Bharmal M. Patient Experiences with Avelumab in Treatment-Naive Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient. 2020 Aug;13(4):457-467. doi: 10.1007\u002Fs40271-020-00428-5.",{"pmid":78,"type":75,"citation":79},"27592805","Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016\u002FS1470-2045(16)30364-3. Epub 2016 Sep 1.",{"pmid":81,"type":75,"citation":82},"32324435","Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbe C, Delord JP, Dunn LA, Shinohara MM, Kulikauskas R, Chung CH, Martens UM, Ferris RL, Stein JE, Engle EL, Devriese LA, Lao CD, Gu J, Li B, Chen T, Barrows A, Horvath A, Taube JM, Nghiem P. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. J Clin Oncol. 2020 Aug 1;38(22):2476-2487. doi: 10.1200\u002FJCO.20.00201. Epub 2020 Apr 23.",[],{"nct_id":4,"conditions":85,"biomarkers":86},[18],[],{"nct_id":4,"found":88,"summary":89,"prompt_version":99},true,{"design":90,"status":91,"heading":92,"summary":93,"follow_up":94,"word_count":95,"commitments":96,"compensation":97,"drugs_mentioned":98},"This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to enroll 500 participants.","completed","Understanding Clinical Trial Engagement in Merkel Cell Carcinoma","This study is looking at why some people with Merkel cell carcinoma (a rare and aggressive skin cancer) join clinical trials and others don't, and what helps people stay in trials until the end. Researchers want to understand if certain factors make it harder for some groups of people to participate or complete trials. By collecting information from 500 participants, this study aims to find patterns that could help improve future clinical trials for Merkel cell carcinoma patients. You can join if you are 18 or older, have Merkel cell carcinoma, and can understand and sign the consent form. The study will measure how many patients decide to join a trial within 3 months and how many stay in a trial for 12 months.","The study will look at how many patients remain in clinical research for up to 12 months.",124,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]